Pfizer Announces Operating Structure and Select Senior Leadership Posts to Be Effective Immediately Upon Close of Wyeth Acquisition

Innovative Approach to Research Supporting Nine Diverse Businesses: Primary
Care, Specialty Care & Vaccines, Emerging Markets, Oncology, Established
Products, Animal Health, Capsugel, Consumer Health, Nutritional Health
NEW YORK--(Business Wire)--
Pfizer (NYSE: PFE) today announced the planned leadership and organizational
structure for its research and commercial operations that will become effective
when the Wyeth acquisition closes.

The company will establish a unique research model designed to advance the
strong scientific capabilities of both Pfizer and Wyeth (NYSE: WYE) and to
support the new company`s nine diverse health care businesses. At the
senior-most level of the organization, Pfizer will retain eight senior
executives from Wyeth who will join the company post-closing.

CEOs Jeff Kindler and Bernard Poussot and senior leadership of both companies
continue to work closely together through the integration process. As planning
continues, additional appointments are expected that will enable Pfizer to begin
appreciating the benefits of the combined company with a new team and structure
in place immediately following the close of the acquisition.

A New Approach for Research

To maximize new opportunities in biopharmaceutical research, Pfizer will form
two distinct research organizations. The PharmaTherapeutics Research Group will
focus on the discovery of small molecules and related modalities and will be led
by Martin Mackay, who now leads Pfizer Global Research & Development (PGRD). The
BioTherapeutics Research Group will focus on large-molecule research, including
vaccines, and will be led by Mikael Dolsten, who currently serves as President
of Wyeth Research. Both Dr. Dolsten and Dr. Mackay will serve as presidents of
their respective organizations and members of Pfizer`s Executive Leadership
Team, and both will report to Pfizer Chairman and Chief Executive Officer Jeff
Kindler.

The new BioTherapeutics Research Group will capitalize on Wyeth`s
industry-leading expertise in biologics and build on the momentum established by
both Pfizer`s Biotherapeutics and Bioinnovation Center (BBC) and centers of
large-molecule research and pharmaceutical science excellence in PGRD, which
will be part of the new, larger group. This new group`s mandate will be to
create a broad and deep pipeline in vaccines, antibodies, proteins, peptides,
nucleic acids and other novel modalities. The PharmaTherapeutics Research Group
will continue to advance the strong legacy of both Pfizer and Wyeth in
small-molecule discovery.

Within these two research groups, small, focused scientific teams - targeting
specific high-potential therapeutic areas and leading-edge innovative
technologies - will be led by world-class Chief Scientific Officers who will act
as single points of accountability for delivering medical advances on behalf of
the company. These teams will be responsible for creating a rich portfolio of
both small and large molecules from across both research organizations and, in
particular, with delivering positive proofs-of-concept for Pfizer`s business
units to develop. They will also aggressively pursue collaborations with top
academic, public-sector and private-sector institutions to accelerate research
and development of new medicines.

The combined scientific teams and programs of the two companies will enable
Pfizer to make significant advances in vaccines and neuroscience, among many
other areas of unmet medical need. In that connection, Emilio Emini, who
currently heads Wyeth`s Vaccine Research; and Development, will join Pfizer as
Chief Scientific Officer, Vaccine Research, and Menelas Pangalos, who currently
serves as Wyeth`s Head of Discovery, will join Pfizer as Chief Scientific
Officer, Neuroscience Research. Dr. Emini and Dr. Pangalos bring incomparable
scientific expertise and outstanding leadership to Pfizer, which are essential
to building the world`s premier biopharmaceutical research and development
organization.

Additionally, Pfizer will form a team of top scientists from both companies who
will seek and evaluate new technologies, platforms and pre-proof-of-concept
small and large molecules from external sources. As this group identifies
promising early-stage candidates from outside the company, it will collaborate
with Pfizer`s business development team to pursue these opportunities. By
complementing Pfizer`s internal research efforts, these scientists will help
assure Pfizer has access to the broadest set of early stage compounds and
technologies available to find new medicines for patients.

"Creating two distinct, but complementary, research organizations, led by the
top scientist from each company, will provide sharper focus, less bureaucracy
and clearer accountability in drug discovery," Mr. Kindler said. "This structure
powerfully states our commitment to becoming the industry leader in small
molecules, large molecules and vaccines. Our approach to research will fuel our
discovery efforts, inspire top talent and translate into high-impact new
medicines for patients. I am honored that world-class scientists like Drs.
Dolsten, Emini and Pangalos will be joining the outstanding scientists at Pfizer
and, as we continue our integration planning, I look forward to our welcoming
many more distinguished Wyeth scientists to our organization."

Enhanced Commercial Operating Structure

The new Pfizer will consist of nine diverse global health care businesses. As is
the case at Pfizer today, the leader of each of the company`s biopharmaceutical
businesses will have clear accountability for results from initial product
development to providing access to patients and through to the end of the
product`s life cycle. The businesses will be led by world-class executives from
both Pfizer and Wyeth who will have the resources to pursue attractive growth
opportunities and to meet the needs of patients and customers around the world.

Ian Read, currently President of Worldwide Pharmaceutical Operations for Pfizer,
will become Group President, Pfizer BioPharmaceutical Businesses, and remain a
member of the Executive Leadership Team reporting to Mr. Kindler. In that
capacity, he will lead a group that includes five leading biopharmaceutical
businesses:

* Primary Care, led by President Olivier Brandicourt, will be the world`s
leading primary care business, with strong positions in cardiovascular (#1),
infectious disease (#2), immunology (#4) and central nervous system diseases
(#2), and with unique research and development opportunities in areas like
Alzheimer`s disease and pain.
* Specialty Care and Vaccines will be led by President Geno Germano, currently
President of Wyeth`s U.S. and Pharmaceuticals business units. It will be the
world`s second largest specialty care business, with prominent positions in
inflammation (#2), vaccines (#4) and immunology (#4); leading products such as
Enbrel, the world`s leading biologic and Prevnar, the world`s leading vaccine;
and a strong pipeline of small- and large-molecule compounds.

Jim Connolly, currently Wyeth`s Executive Vice President & General Manager,
Vaccines, will join the Specialty Care and Vaccines Business Unit as President,
Vaccines, reporting to Mr. Germano. He will lead an integrated vaccine business
comprising marketing, sales and medical affairs, which will align closely with
the Vaccine Research group led by Dr. Emini. They will work together to bring
innovative new vaccines to patients around the globe.

* Emerging Markets will continue to be led by President Jean-Michel Halfon and
will have a significantly enhanced presence in high-growth, less-developed and
under-penetrated markets, including those in Latin America, the Middle East and
China.
* Oncology will continue to be led by President Garry Nicholson and will
continue to bring patients important treatments like Sutent. It will also bring
to market one of the most robust oncology product pipelines in the
biopharmaceutical industry, one that includes compounds focusing on diverse
tumor types including lung, colorectal, liver, prostate and breast.
* Established Products will continue to be led by President David Simmons and
will continue to be a strong global business in a marketplace that is expected
to see significant growth in the years ahead. Through portfolio enhancement and
expansion activities, including new partnerships, Established Products will
continue to extend Pfizer`s reach into this important market segment.

Cavan Redmond, currently President of Wyeth`s Consumer Healthcare business, will
become Group President, Pfizer Diversified Businesses, join Pfizer`s Executive
Leadership Team and report to Mr. Kindler. This group will include four unique
businesses, each meeting important customer needs and offering significant
growth:

* Animal Health will continue to be led by President Juan-Ramón Alaix and will
have an enhanced leading position in the industry, with important large animal
and companion animal products and a platform that includes vaccines,
parasiticides and anti-infectives.
* Capsugel will continue to be led by President Guido Driesen and will continue
to be the world's pre-eminent manufacturer and developer of capsule products,
equipment and services for the pharmaceutical and associated health care
industries.
* Consumer Health will be led by President Paul Sturman, currently President,
U.S. and Global Business Development, New Products for Wyeth Consumer
Healthcare. Consumer Health will remain a leader in analgesics,
cough/cold/allergy and vitamin/nutritional supplements, including brands such as
Advil, Caltrate, Centrum, ChapStick, Robitussin and ThermaCare.
* Nutritional Health will be led by President Erica Mann, currently Managing
Director of Wyeth Australia and New Zealand. The Nutritional business at Wyeth
operates in more than 50 countries and has a portfolio that includes a full line
of nutritional products, including infant formulas, follow-on formulas,
growing-up milks, and prenatal and adult supplements.

Mr. Kindler stated: "By putting together these businesses and combining in one
team a number of strong and experienced Pfizer and Wyeth leaders, we are
creating the world`s premier biopharmaceutical company - one that is powerfully
positioned to provide substantial value for patients, customers, colleagues and
shareholders."

Integration Progress

Added Chief Financial Officer Frank D`Amelio, who is leading the integration on
behalf of Pfizer: "With today`s announcement we have taken another significant
step in preparing for the combining of these two great companies. Having our
organizational structure in place is critical to the combined company being
operational on Day One, and the appointment of these leaders will accelerate our
ability to do so.

"We have made substantial progress in a short period of time, particularly in
financing, as well as other requirements for closing. Our progress affirms how
well these two companies fit together, the value of this combination, and the
commitment of our companies to rapid and successful integration," Mr. D`Amelio
said.

Mr. Kindler noted: "I want particularly to thank Wyeth Chief Executive Officer
Bernard Poussot for his strong and steady leadership and his partnership. He is
an instrumental part of our integration efforts and will continue to provide us
with critical counsel and support until the close of the acquisition. Bernard`s
commitment to Wyeth leaders and to the success of the combined company is
extraordinary.

"We look forward to welcoming these new colleagues and I am confident Pfizer
will be strengthened by the addition of many other exceptional Wyeth scientists
and business leaders. They will join Pfizer colleagues with whom they share a
commitment to delivering the full potential of the Pfizer-Wyeth combination to
patients, customers and investors," Mr. Kindler concluded.

The leadership team will begin working together immediately upon the completion
of the acquisition. Until the acquisition is complete, Pfizer and Wyeth
leadership will continue in their current roles. Pfizer announced on January 26,
2009, that it is acquiring Wyeth in a cash-and-stock transaction to create the
world`s premier biopharmaceutical company. The acquisition remains subject to
customary closing conditions, including approval by the stockholders of Wyeth,
and regulatory approval in certain jurisdictions. Pfizer and Wyeth continue to
expect the transaction to close at the end of the third quarter or during the
fourth quarter of 2009.

ABOUT PFIZER

Pfizer Inc, founded in 1849, is dedicated to better health and greater access to
health care for people and their valued animals. Every day, more than 80,000
colleagues in more than 90 countries work to discover, develop, manufacture and
deliver quality, safe and effective prescription medicines to patients.

ABOUT WYETH

Wyeth is one of the world's largest research-driven pharmaceutical and health
care products companies. It is a leader in the discovery, development,
manufacturing and marketing of pharmaceuticals, vaccines, biotechnology
products, nutritionals and non-prescription medicines that improve the quality
of life for people worldwide. Wyeth's major divisions include Wyeth
Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. Such statements may include, but are not limited to,
statements about the benefits of the proposed merger between Pfizer and Wyeth,
including future financial and operating results, the combined company's plans,
objectives, expectations and intentions and other statements that are not
historical facts. Such statements are based upon the current beliefs and
expectations of Pfizer's and Wyeth's management and are subject to significant
risks and uncertainties. Actual results may differ from those set forth in the
forward-looking statements. Neither Pfizer nor Wyeth undertake any obligation to
update publicly or revise any forward-looking statements. The following factors,
among others, could cause actual results to differ from those set forth in the
forward-looking statements: the possibility that the expected synergies from the
proposed merger of Pfizer and Wyeth will not be realized, or will not be
realized within the expected time period, due to, among other things, the impact
of pharmaceutical industry regulation and pending legislation that could affect
the pharmaceutical industry; the ability to obtain governmental and
self-regulatory organization approvals of the merger on the proposed terms and
schedule; the failure of Wyeth stockholders to approve the merger; the risk that
the businesses will not be integrated successfully; disruption from the merger
making it more difficult to maintain business and operational relationships; the
possibility that the merger does not close, including, but not limited to, due
to the failure to satisfy the closing conditions; Pfizer's and Wyeth's ability
to accurately predict future market conditions; dependence on the effectiveness
of Pfizer's and Wyeth's patents and other protections for innovative products;
the risk of new and changing regulation and health policies in the U.S. and
internationally and the exposure to litigation and/or regulatory actions.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Pfizer's 2008 Annual
Report on Form 10-K filed with the Securities and Exchange Commission (the
"SEC") on February 27, 2009, Wyeth's 2008 Annual Report on Form 10-K filed with
the SEC on February 27, 2009, including in the "Risk Factors" section of each of
these filings, and each company's other filings with the SEC available at the
SEC's Internet site (http://www.sec.gov).

Additional Information

In connection with the proposed acquisition of Wyeth, Pfizer filed with the SEC
a Registration Statement on Form S-4 on March 27, 2009 that includes a
preliminary proxy statement of Wyeth that also constitutes a prospectus of
Pfizer. At the appropriate time, Wyeth will mail the final proxy
statement/prospectus to its stockholders. Pfizer and Wyeth urge investors and
security holders to read the proxy statement/prospectus regarding the proposed
acquisition because it contains important information. You may obtain copies of
all documents filed with the SEC regarding this transaction, free of charge, at
the SEC`s website (www.sec.gov). You may also obtain these documents, free of
charge, from Pfizer`s website, www.pfizer.com, under the tab "Investors" and
then under the tab "SEC Filings". You may also obtain these documents, free of
charge, from Wyeth`s website, www.wyeth.com, under the heading "Investor
Relations" and then under the tab "Financial Reports/SEC Filings". Pfizer, Wyeth
and their respective directors, executive officers and certain other members of
management and employees may be soliciting proxies from Wyeth stockholders in
favor of the proposed acquisition. Information regarding the persons who may,
under the rules of the SEC, be deemed participants in the solicitation of the
Wyeth stockholders in connection with the proposed acquisition is set forth in
the proxy statement/prospectus. You can find information about Pfizer`s
executive officers and directors in its definitive proxy statement filed with
the SEC on March 13, 2009. You can find information about Wyeth`s executive
officers and directors in its preliminary proxy statement filed with the SEC on
March 27, 2009 by Pfizer on Form S-4.

Pfizer Inc
Media:
Ray Kerins, 212-733-9203
Joan Campion, 212-733-2798
or
Investors:
Suzanne Harnett, 212-733-8009
Jennifer Davis, 212-733-0717

Copyright Business Wire 2009